Does Rallies show Form 4 insider transactions for IMVT?

Yes. Rallies tracks IMVT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IMVT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMVT. It does not provide personalized investment advice.

IMVT (Immunovant, Inc. Common Stock) Stock Analysis - Insider Trades

Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of May 20, 2026, IMVT trades at $35.27 with a market cap of $5.40B and a P/E ratio of -9.53. IMVT moved +31.65% today. Year to date, IMVT is +1.47%; over the trailing twelve months it is +78.84%. Its 52-week range spans $12.72 to $32.10. Analyst consensus is strong buy with an average price target of $44.88. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IMVT stock inside the company?

Recent IMVT insider activity includes Susman Robert Graham sold 2.50K, Girao Tiago sold 25.76K, Stout Jay S sold 2.75K, Van Tuyl Christopher sold 5.17K, and Gloria Melanie sold 8.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IMVT Key Metrics

Key financial metrics for IMVT
Metric	Value
Price	$35.27
Market Cap	$5.40B
P/E Ratio	-9.53
EPS	$-2.73
Dividend Yield	0.00%
52-Week High	$32.10
52-Week Low	$12.72
Volume	9.31M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-413.84M
Gross Margin	0.00%

Recent IMVT Insider Trades

Susman Robert Graham sold 2.50K (~$67.98K) on May 1, 2026.
Girao Tiago sold 25.76K (~$763.01K) on Apr 23, 2026.
Stout Jay S sold 2.75K (~$81.57K) on Apr 23, 2026.
Van Tuyl Christopher sold 5.17K (~$128.25K) on Apr 8, 2026.
Gloria Melanie sold 8.72K (~$216.57K) on Apr 8, 2026.

Latest IMVT News

IMVT-1402 Shows 72.7% ACR20 Response in D2T RA; $902M Cash Runway — May 20, 2026
Immunovant climbs as attention shifts back to IMVT-1402 after batoclimab TED setback — May 6, 2026
Immunovant slips as investors keep discounting batoclimab after Phase 3 TED miss — Apr 28, 2026
Immunovant slides as investors weigh April insider sale and mid-April Hold call — Apr 23, 2026
Immunovant climbs as Wall Street lifts targets and shares hover near new highs — Apr 22, 2026

IMVT Analyst Consensus

8 analysts cover IMVT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.88.

Common questions about IMVT

Who is trading IMVT stock inside the company?: Recent IMVT insider activity includes Susman Robert Graham sold 2.50K, Girao Tiago sold 25.76K, Stout Jay S sold 2.75K, Van Tuyl Christopher sold 5.17K, and Gloria Melanie sold 8.72K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IMVT?: Yes. Rallies tracks IMVT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IMVT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMVT. It does not provide personalized investment advice.